With the 2014-2015 Flu season on the horizon, the United States Food and Drug Administration (“FDA”) has recently approved the first needle-free system for the administration of an inactive influenza vaccine. On August 15, 2014, the FDA approved the use of Afluria®, an inactive influenza vaccine, to be administered by intramuscular injection with the PharmaJet Stratis® Needle-Free Injection System based on its evaluation of supporting safety and effectiveness data. As a result, now healthcare providers have another arrow in the quiver of options when considering the delivery of the seasonal flu vaccine to certain individuals.
Rather than the traditional method of administration, the PharmaJet® injector delivers the vaccine by means of a narrow, precise fluid stream that penetrates the skin in about one-tenth of a second. One of the driving forces behind the invention of a needle-free method of administration of the flu vaccine is an attempt to capture those individuals who forego the seasonal flu vaccine due to needle phobia. In addition, another upside to eliminating the needle is the potential reduction of needle stick injuries sustained by healthcare workers who are administering the vaccine.
Currently, Afluria® is the only inactivated influenza vaccine labeled for administration via a jet injector and is only recommended for use in 18-64 year olds. With respect to the other vaccines on the market, the FDA continues to recommend that other inactive influenza vaccines be administered the old fashion way, via needle and syringe.
To contact our vaccine injury lawyers, or to read more about the National Vaccine Injury Compensation Program, please click here.